相关实验视频

Updated: Jul 27, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

在KRAS中,氨酸与氧化基双剂相比,氨酸与氧化基双剂

Vincenzo Formica¹, Cristina Morelli¹, Veronica Conca²

¹Medical Oncology Unit, Department of Medicine of the Systems, University of Rome Tor Vergata, 00133 Rome, Italy.

|June 10, 2023

概括

与基于oxaliplatin的疗法相比,一线的伊利诺特干化疗为患有KRASG12C突变转移性结直肠癌的患者提供更好的生存结果. 这一发现对于优化治疗策略至关重要.

科学领域:

在瘤学瘤学.
医学遗传学医学遗传学
临床药理学临床药理学

背景情况:

KRASG12C突变转移性结直肠癌 (mCRC) 是一种独特的分子亚型,具有有限的化疗敏感性数据.
与KRASG12C抑制剂联合治疗的最佳化疗骨干目前尚不清楚.
了解这种特定的mCRC群体的化疗反应对于未来的治疗进展至关重要.

研究的目的:

为了比较一线FOLFIRI与FOLFOX化疗在KRASG12C突变mCRC.患者中的疗效.
为了确定KRASG12C突变mCRC.的首选化疗方案.
为了为涉及KRASG12C抑制剂的组合疗法的化疗骨干的选择提供信息.

主要方法:

对KRASG12C突变mCRC患者的多中心回顾性分析,这些患者接受了第一线FOLFIRI或FOLFOX +/- 贝瓦西祖马布治疗.
倾向性得分匹配分析 (PSMA) 用于控制关键患者和疾病特征.
进行了子组分析,以探索治疗效果相互作用.

主要成果:

在倾向性得分匹配的队列中,与基于氧沙利的疗法相比,基于伊利诺特干的疗法显著改善了无进展生存 (PFS) 和整体生存 (OS).
在12个月的PFS率是55%的伊利诺特干与31%的oxaliplatin (HR 0.40,p=0.01).
平均生存期为37.9个月,与21.7个月与氧化 (HR0.45,p=0.045) 相比.

结论:

一线依赖伊利诺特干的化疗显著提高了KRASG12C突变mCRC患者的生存结果.
在这种患者群体中,应优先选择基于 irinotekan 的疗法而不是 oxaliplatin.
这些结果对未来的向治疗组合中选择化疗骨干有影响.

关键词:

这就是KRASG12C突变.氨酸的作用: 氨酸的作用是:转移性结直肠癌转移性结直肠癌氧化合金是一种氧化.

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Published on: May 5, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...